Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20571090 | 0.97 | NR1H2 (0.43) | NR1H2NR1H3SLC6A3KCNH2GPR119 | |
| SCHEMBL23985956 | 0.87 | GPR119 (0.46) | NR1H2NR1H3KCNH2GPR119EGFR | |
| SCHEMBL26243059 | 0.87 | MAP4K4 (0.40) | NR1H2NR1H3SLC6A3GPR119EGFR | |
| SCHEMBL24425025 | 0.87 | MAP4K4 (0.40) | NR1H2NR1H3SLC6A3GPR119EGFR | |
| SCHEMBL25383219 | 0.86 | SLC6A3 (0.41) | SLC6A3GRM4SIGMAR1 | |
| SCHEMBL16636900 | 0.85 | MAPK8 (0.39) | NR1H2NR1H3KCNH2GPR119RET | |
| SCHEMBL16636974 | 0.85 | MAPK8 (0.39) | NR1H2NR1H3KCNH2GPR119RET | |
| SCHEMBL21136711 | 0.84 | MAPK8 (0.41) | NR1H2NR1H3KCNH2GPR119 | |
| SCHEMBL21136735 | 0.84 | KCNH2 (0.47) | KCNH2GPR119 | |
| SCHEMBL29876522 | 0.84 | KCNH2 (0.49) | NR1H2NR1H3KCNH2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406849-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2023-12-21 | — | — | US | disclosed |
| CN-113563323-B | Benzothiazolyl biaryl compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-116867779-A | KRAS inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-4242207-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| EP-4242207-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| US-20230174526-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | SHANGHAI RINGENE THERAPEUTICS CO. LTD (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174526-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | SHANGHAI RINGENE THERAPEUTICS CO. LTD (CN) | 2023-06-08 | — | — | US | disclosed |
| EP-4144732-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | Shanghai Ringene BioPharma Co., Ltd. (CN) | 2023-03-08 | — | — | EP | disclosed |
| EP-4144732-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | Shanghai Ringene BioPharma Co., Ltd. (CN) | 2023-03-08 | — | — | EP | disclosed |
| CN-114920738-A | KRas inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022095960-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | 泰励生物科技（上海）有限公司 | 2022-05-12 | — | — | WO | disclosed |
| WO-2021218110-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | 上海凌达生物医药有限公司 | 2021-11-04 | — | — | WO | disclosed |
| CN-113563323-A | Benzothiazolyl biaryl compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | ARAXES PHARMA LLC (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3630746-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | Araxes Pharma LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-110869357-A | Compounds and methods of use thereof for treating cancer | 亚瑞克西斯制药公司 | 2020-03-06 | — | — | CN | disclosed |
| WO-2018218071-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | KRAS, NRAS, HRAS | NR1H2 2430/4885NR1H3 2387/4885SLC6A3 4231/4885 |
| US-20230406849-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | KRAS, NRAS, HRAS | NR1H2 2505/4885NR1H3 2645/4885SLC6A3 4808/4885 |
| US-20230174526-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | KRAS, NRAS, HRAS | NR1H2 2047/4885NR1H3 1920/4885SLC6A3 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.